Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells

Grzegorz W. Basak, Ozren Jaksic, Zdenek Koristek, G. Mikala, Sandra Basic-Kinda, Jiri Mayer, T. Masszi, Sebastian Giebel, Boris Labar, Wieslaw Wiktor-Jedrzejczak

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the intensity and number of previous therapies. We observed that the median peripheral blood concentration of CD34+ cells after the first administration of plerixafor was lower in previously transplanted (19cells/μL) than in other patients (30cells/μL, P6cells/kg vs. 4.2×106cells/kg, P6CD34+ cells/kg was achieved finally in a similar proportion of previously transplanted and other patients (70% vs. 82.6%). Our data suggest that stem cell mobilization with plerixafor and G-CSF might overcome the negative effect of prognostic factors for poor stem cell mobilization in patients with MM who have undergone autoSCT previously.

Original languageEnglish
Pages (from-to)488-495
Number of pages8
JournalEuropean Journal of Haematology
Volume86
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Hematopoietic Stem Cell Mobilization
Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Stem Cells
Stem Cell Transplantation
JM 3100
Transplantation

Keywords

  • Autologous stem cell transplantation
  • Myeloma
  • Plerixafor
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology

Cite this

Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. / Basak, Grzegorz W.; Jaksic, Ozren; Koristek, Zdenek; Mikala, G.; Basic-Kinda, Sandra; Mayer, Jiri; Masszi, T.; Giebel, Sebastian; Labar, Boris; Wiktor-Jedrzejczak, Wieslaw.

In: European Journal of Haematology, Vol. 86, No. 6, 06.2011, p. 488-495.

Research output: Contribution to journalArticle

Basak, Grzegorz W. ; Jaksic, Ozren ; Koristek, Zdenek ; Mikala, G. ; Basic-Kinda, Sandra ; Mayer, Jiri ; Masszi, T. ; Giebel, Sebastian ; Labar, Boris ; Wiktor-Jedrzejczak, Wieslaw. / Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. In: European Journal of Haematology. 2011 ; Vol. 86, No. 6. pp. 488-495.
@article{50cf7d8b0daf4999b890bb5a70e3a941,
title = "Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells",
abstract = "A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the intensity and number of previous therapies. We observed that the median peripheral blood concentration of CD34+ cells after the first administration of plerixafor was lower in previously transplanted (19cells/μL) than in other patients (30cells/μL, P6cells/kg vs. 4.2×106cells/kg, P6CD34+ cells/kg was achieved finally in a similar proportion of previously transplanted and other patients (70{\%} vs. 82.6{\%}). Our data suggest that stem cell mobilization with plerixafor and G-CSF might overcome the negative effect of prognostic factors for poor stem cell mobilization in patients with MM who have undergone autoSCT previously.",
keywords = "Autologous stem cell transplantation, Myeloma, Plerixafor, Stem cell mobilization",
author = "Basak, {Grzegorz W.} and Ozren Jaksic and Zdenek Koristek and G. Mikala and Sandra Basic-Kinda and Jiri Mayer and T. Masszi and Sebastian Giebel and Boris Labar and Wieslaw Wiktor-Jedrzejczak",
year = "2011",
month = "6",
doi = "10.1111/j.1600-0609.2011.01605.x",
language = "English",
volume = "86",
pages = "488--495",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells

AU - Basak, Grzegorz W.

AU - Jaksic, Ozren

AU - Koristek, Zdenek

AU - Mikala, G.

AU - Basic-Kinda, Sandra

AU - Mayer, Jiri

AU - Masszi, T.

AU - Giebel, Sebastian

AU - Labar, Boris

AU - Wiktor-Jedrzejczak, Wieslaw

PY - 2011/6

Y1 - 2011/6

N2 - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the intensity and number of previous therapies. We observed that the median peripheral blood concentration of CD34+ cells after the first administration of plerixafor was lower in previously transplanted (19cells/μL) than in other patients (30cells/μL, P6cells/kg vs. 4.2×106cells/kg, P6CD34+ cells/kg was achieved finally in a similar proportion of previously transplanted and other patients (70% vs. 82.6%). Our data suggest that stem cell mobilization with plerixafor and G-CSF might overcome the negative effect of prognostic factors for poor stem cell mobilization in patients with MM who have undergone autoSCT previously.

AB - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the intensity and number of previous therapies. We observed that the median peripheral blood concentration of CD34+ cells after the first administration of plerixafor was lower in previously transplanted (19cells/μL) than in other patients (30cells/μL, P6cells/kg vs. 4.2×106cells/kg, P6CD34+ cells/kg was achieved finally in a similar proportion of previously transplanted and other patients (70% vs. 82.6%). Our data suggest that stem cell mobilization with plerixafor and G-CSF might overcome the negative effect of prognostic factors for poor stem cell mobilization in patients with MM who have undergone autoSCT previously.

KW - Autologous stem cell transplantation

KW - Myeloma

KW - Plerixafor

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=79956010685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956010685&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2011.01605.x

DO - 10.1111/j.1600-0609.2011.01605.x

M3 - Article

C2 - 21410533

AN - SCOPUS:79956010685

VL - 86

SP - 488

EP - 495

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -